|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Merck & Co.’s (MRK) Zetia generated revenues of $165 million in the third quarter, reflecting a ~48% YoY (year-over-year) decline and a ~27% sequential decline. Zetia reported net revenues of $696 million in the first nine months of the year compared to $1 billion in the same period of 2017, reflecting a ~32% YoY decline.
In the second quarter of 2018, Merck’s (MRK) Zetia generated revenues of $226.0 million compared to $367.0 million in the second quarter of 2017, reflecting a ~38% year-over-year (or YoY) decline and a ~26% sequential decline. In the second quarter of 2018, in the US and international markets (outside the US markets), Zetia generated revenues of $8.0 million and $218.0 million, respectively, compared to $122.0 million and $246.0 million in the second quarter of 2017.
Impax Asset Management Group plc (LON:IPX), a capital markets company based in United Kingdom, led the AIM gainers with a relatively large price hike in the past couple of weeks.Read More...